Management of hepatitis C; Report of the Consensus Meeting at the 45th Annual Meeting of the Japan Society of Hepatology (2009)
暂无分享,去创建一个
M. Kudo | N. Hayashi | N. Hiramatsu | A. Tamori | H. Kumada | S. Nishiguchi | F. Suzuki | K. Hino | Y. Itoh | Izumi Namiki | Y. Asahina
[1] S. Takagi,et al. Natural History , 2019, Nature.
[2] Y. Imai,et al. Factors affecting efficacy in patients with genotype 2 chronic hepatitis C treated by pegylated interferon alpha‐2b and ribavirin: reducing drug doses has no impact on rapid and sustained virological responses , 2010, Journal of viral hepatitis.
[3] Y. Imai,et al. Pegylated interferon alpha‐2b (Peg‐IFN α‐2b) affects early virologic response dose‐dependently in patients with chronic hepatitis C genotype 1 during treatment with Peg‐IFN α‐2b plus ribavirin , 2009, Journal of viral hepatitis.
[4] Y. Imai,et al. Ribavirin dose reduction raises relapse rate dose‐dependently in genotype 1 patients with hepatitis C responding to pegylated interferon alpha‐2b plus ribavirin , 2009, Journal of viral hepatitis.
[5] Yoshiyuki Suzuki,et al. Poor Response to Pegylated Interferon and Ribavirin in Older Women Infected with Hepatitis C Virus of Genotype 1b in High Viral Loads , 2009, Digestive Diseases and Sciences.
[6] M. Sata,et al. A randomized trial of 24 versus 48 weeks of peginterferon α-2a in patients infected with chronic hepatitis C virus genotype 2 or low viral load genotype 1: a multicenter national study in Japan , 2009, Hepatology international.
[7] Yoshiyuki Suzuki,et al. Necessities of interferon therapy in elderly patients with chronic hepatitis C. , 2009, The American journal of medicine.
[8] E. Schiff,et al. Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy. , 2009, Gastroenterology.
[9] A. Branch,et al. Mutations in the Hepatitis C Virus core Gene Are Associated with Advanced Liver Disease and Hepatocellular Carcinoma , 2009, Clinical Cancer Research.
[10] Yusuke Nakamura,et al. A polymorphism in MAPKAPK3 affects response to interferon therapy for chronic hepatitis C. , 2009, Gastroenterology.
[11] G. Everson,et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. , 2009, The New England journal of medicine.
[12] P. Marcellin,et al. Re-treatment of Patients With Chronic Hepatitis C Who Do Not Respond to Peginterferon-2b , 2009, Annals of Internal Medicine.
[13] M. Buti,et al. 141 EXTENDED TREATMENT DURATION IN CHRONIC HEPATITIS C GENOTYPE 1-INFECTED SLOW RESPONDERS: FINAL RESULTS OF THE SUCCESS STUDY , 2009 .
[14] M. Ghany,et al. Diagnosis, management, and treatment of hepatitis C: An update , 2009, Hepatology.
[15] B. Bacon,et al. Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: A 5‐year follow‐up of 150 patients , 2009, Hepatology.
[16] T. Arakawa,et al. Long‐term follow‐up of patients with hepatitis C with a normal alanine aminotransferase , 2009, Journal of medical virology.
[17] Yoshiyuki Suzuki,et al. A matched case‐controlled study of 48 and 72 weeks of peginterferon plus ribavirin combination therapy in patients infected with HCV genotype 1b in Japan: amino acid substitutions in HCV core region as predictor of sustained virological response , 2009, Journal of medical virology.
[18] A. Andriulli,et al. Determinants of relapse after a short (12 weeks) course of antiviral therapy and re‐treatment efficacy of a prolonged course in patients with chronic hepatitis C virus genotype 2 or 3 infection , 2009, Hepatology.
[19] Charles M. Rice,et al. Human occludin is a hepatitis C virus entry factor required for infection of mouse cells , 2009, Nature.
[20] T. Ide,et al. A Randomized Study of Extended Treatment With Peginterferon α-2b Plus Ribavirin Based on Time to HCV RNA Negative–Status in Patients With Genotype 1b Chronic Hepatitis C , 2009, The American Journal of Gastroenterology.
[21] Y. Kondo,et al. Pegylated interferon plus ribavirin for genotype Ib chronic hepatitis C in Japan. , 2008, World journal of gastroenterology.
[22] S. Fargion,et al. Iron stores, response to alpha-interferon therapy, and effects of iron depletion in chronic hepatitis C. , 2008, Liver.
[23] O. Weiland,et al. Outcome of acute symptomatic non-A, non-B hepatitis: a 13-year follow-up study of hepatitis C virus markers. , 2008, Liver.
[24] William M. Lee,et al. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. , 2008, The New England journal of medicine.
[25] N. Tanaka,et al. Pretreatment prediction of virological response to peginterferon plus ribavirin therapy in chronic hepatitis C patients using viral and host factors , 2008, Hepatology.
[26] D. Brenner,et al. Hepatitis C virus–induced oxidative stress suppresses hepcidin expression through increased histone deacetylase activity , 2008, Hepatology.
[27] O. Weiland,et al. Lower‐than‐standard dose peg‐IFN alfa‐2a for chronic hepatitis C caused by genotype 2 and 3 is sufficient when given in combination with weight‐based ribavirin , 2008, Journal of viral hepatitis.
[28] Yoshiyuki Suzuki,et al. Efficacy of low-dose intermittent interferon-alpha monotherapy in patients infected with hepatitis C virus genotype 1b who were predicted or failed to respond to pegylated interferon plus ribavirin combination therapy. , 2008, Journal of medical virology.
[29] P. Messa,et al. Antiviral therapy of hepatitis C in chronic kidney diseases: meta‐analysis of controlled clinical trials , 2008, Journal of viral hepatitis.
[30] H. Hotta,et al. Sequence variation in hepatitis C virus nonstructural protein 5A predicts clinical outcome of pegylated interferon/ribavirin combination therapy , 2008, Hepatology.
[31] G. Norkrans,et al. Randomized comparison of 12 or 24 weeks of peginterferon α‐2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection , 2008, Hepatology.
[32] M. Manns,et al. Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus , 2008, Hepatology.
[33] N. Enomoto,et al. Potential relevance of cytoplasmic viral sensors and related regulators involving innate immunity in antiviral response. , 2008, Gastroenterology.
[34] J. Dubuisson,et al. Early steps of the hepatitis C virus life cycle , 2008, Cellular microbiology.
[35] A. Macleod. KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. , 2008, Kidney international. Supplement.
[36] Brian L. Pearlman,et al. Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis c genotype 1–infected slow responders , 2007, Hepatology.
[37] E. Bjornsson,et al. Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response , 2007, Hepatology.
[38] Yoshiyuki Suzuki,et al. Amino acid substitutions in the hepatitis C virus core region are the important predictor of hepatocarcinogenesis , 2007, Hepatology.
[39] Yoshiyuki Suzuki,et al. Predictors of viral kinetics to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b , 2007, Journal of medical virology.
[40] R. D. de Knegt,et al. γ‐Glutamyltransferase and rapid virological response as predictors of successful treatment with experimental or standard peginterferon‐α‐2b in chronic hepatitis C non‐responders , 2007 .
[41] R. Gish,et al. Efficacy of interferon alpha‐2b induction therapy before retreatment for chronic hepatitis C , 2007, Liver international : official journal of the International Association for the Study of the Liver.
[42] Yoshiyuki Suzuki,et al. Evaluation of long‐term biochemical responses to combination therapy of interferon plus ribavirin in those infected with hepatitis C virus genotype 1b and high baseline viral load , 2007, Hepatology research : the official journal of the Japan Society of Hepatology.
[43] M. Diago,et al. Clinical trial: pharmacodynamics and pharmacokinetics of re‐treatment with fixed‐dose induction of peginterferon α‐2a in hepatitis C virus genotype 1 true non‐responder patients , 2007, Alimentary pharmacology & therapeutics.
[44] Yoshiyuki Suzuki,et al. Interferon-induced prolonged biochemical response reduces hepatocarcinogenesis in hepatitis C virus infection. , 2007, Journal of medical virology.
[45] H. Hotta,et al. Risk of hepatocellular carcinoma and secondary structure of hepatitis C virus (HCV) NS3 protein amino-terminus, in patients infected with HCV subtype 1b. , 2007, The Journal of infectious diseases.
[46] P. Messa,et al. Interferon monotherapy of chronic hepatitis C in dialysis patients: meta‐analysis of clinical trials , 2007, Journal of viral hepatitis.
[47] R. Stravitz,et al. Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha , 2007, Hepatology.
[48] Yoshiyuki Suzuki,et al. Prolonged‐interferon therapy reduces hepatocarcinogenesis in aged‐patients with chronic hepatitis C , 2007, Journal of medical virology.
[49] B. Bacon,et al. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. , 2007, The New England journal of medicine.
[50] H. Nomura,et al. Efficacy of low dose long‐term interferon monotherapy in aged patients with chronic hepatitis C genotype 1 and its relation to alpha‐fetoprotein: A pilot study , 2007, Hepatology research : the official journal of the Japan Society of Hepatology.
[51] K. Tanikawa,et al. A Large-scale, Multicentre, Double-blind Trial of Ursodeoxycholic Acid in Patients with Chronic Hepatitis C , 2022 .
[52] M. Kurosaki,et al. Pharmacokinetics and enhanced PKR response in patients with chronic hepatitis C treated with pegylated interferon alpha‐2b and ribavirin , 2007, Journal of viral hepatitis.
[53] Milton W. Taylor,et al. Pretreatment Sequence Diversity Differences in the Full-Length Hepatitis C Virus Open Reading Frame Correlate with Early Response to Therapy , 2007, Journal of Virology.
[54] H. Toyoda,et al. Relation between incidence of hepatic carcinogenesis and integration value of alanine aminotransferase in patients with hepatitis C virus infection , 2007, Gut.
[55] Charles M. Rice,et al. Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry , 2007, Nature.
[56] A. Mangia,et al. Sustained virological response to interferon‐α is associated with improved outcome in HCV‐related cirrhosis: A retrospective study , 2007, Hepatology.
[57] Yoshiyuki Suzuki,et al. Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels. , 2007, Journal of hepatology.
[58] Keiji Tanaka,et al. Critical role of PA28γ in hepatitis C virus-associated steatogenesis and hepatocarcinogenesis , 2007, Proceedings of the National Academy of Sciences.
[59] L. Mariani,et al. Prevention of hepatocellular carcinoma recurrence with alpha‐interferon after liver resection in HCV cirrhosis , 2006, Hepatology.
[60] J. Borovička,et al. HCV‐related advanced fibrosis/cirrhosis: randomized controlled trial of pegylated interferon α‐2a and ribavirin , 2006, Journal of viral hepatitis.
[61] L. Rostaing,et al. Treatment of hepatitis C virus infection (HCV) after renal transplantation: implications for HCV-positive dialysis patients awaiting a kidney transplant. , 2006, Transplantation.
[62] T. Mcgarrity,et al. Sustained Viral Response to Pegylated Interferon α-2b and Ribavirin in Chronic Hepatitis C Refractory to Prior Treatment , 2006, Digestive Diseases and Sciences.
[63] Ming‐Lung Yu,et al. A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C , 2006, Gut.
[64] Christopher T. Jones,et al. Diverse CD81 Proteins Support Hepatitis C Virus Infection , 2006, Journal of Virology.
[65] R. Andrade,et al. Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. , 2006, Gastroenterology.
[66] N. Hayashi,et al. Should aged patients with chronic hepatitis C be treated with interferon and ribavirin combination therapy? , 2006, Hepatology research : the official journal of the Japan Society of Hepatology.
[67] R. Suruki,et al. Alanine aminotransferase level as a predictor of hepatitis C virus‐associated hepatocellular carcinoma incidence in a community‐based population in Japan , 2006, International Journal of Cancer.
[68] S. Lemon,et al. Hepatic iron overload induces hepatocellular carcinoma in transgenic mice expressing the hepatitis C virus polyprotein. , 2006, Gastroenterology.
[69] William M. Lee,et al. Viral and therapeutic control of IFN-beta promoter stimulator 1 during hepatitis C virus infection. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[70] T. Berg,et al. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. , 2006, Gastroenterology.
[71] Yoshiyuki Suzuki,et al. A Long-Term Glycyrrhizin Injection Therapy Reduces Hepatocellular Carcinogenesis Rate in Patients with Interferon-Resistant Active Chronic Hepatitis C: A Cohort Study of 1249 Patients , 2006, Digestive Diseases and Sciences.
[72] Y. Shiratori,et al. Limitation of combination therapy of interferon and ribavirin for older patients with chronic hepatitis C , 2006, Hepatology.
[73] J. Kaldor,et al. Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies , 2006, Journal of viral hepatitis.
[74] S. Weinman,et al. Hepatitis C Virus Core Protein Inhibits Mitochondrial Electron Transport and Increases Reactive Oxygen Species (ROS) Production* , 2005, Journal of Biological Chemistry.
[75] E. Bini,et al. A Randomized Trial of Pegylated Interferon α-2b Plus Ribavirin in the Retreatment of Chronic Hepatitis C , 2005, The American Journal of Gastroenterology.
[76] Osamu Takeuchi,et al. IPS-1, an adaptor triggering RIG-I- and Mda5-mediated type I interferon induction , 2005, Nature Immunology.
[77] T. Nakajima,et al. A follow-up study to determine the value of liver biopsy and need for antiviral therapy for hepatitis C virus carriers with persistently normal serum aminotransferase. , 2005, Journal of hepatology.
[78] T. Hibi,et al. Effect of long-term interferon therapy for refractory chronic hepatitis c: preventive effect on hepatocarcinogenesis. , 2005, Hepato-gastroenterology.
[79] M. Gale,et al. Evasion of intracellular host defence by hepatitis C virus , 2005, Nature.
[80] T. Berg,et al. Peginterferon-α-2a (40KD) and Ribavirin for 16 or 24 Weeks in Patients With Genotype 2 or 3 Chronic Hepatitis C , 2005 .
[81] Yoshiyuki Suzuki,et al. Association of Amino Acid Substitution Pattern in Core Protein of Hepatitis C Virus Genotype 1b High Viral Load and Non-Virological Response to Interferon-Ribavirin Combination Therapy , 2005, Intervirology.
[82] A. Andriulli,et al. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. , 2005, The New England journal of medicine.
[83] B. Neuschwander‐Tetri,et al. Effect of significant histologic steatosis or steatohepatitis on response to antiviral therapy in patients with chronic hepatitis C. , 2005, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[84] S. Lemon,et al. Distinct Poly(I-C) and Virus-activated Signaling Pathways Leading to Interferon-β Production in Hepatocytes* , 2005, Journal of Biological Chemistry.
[85] H. Te,et al. Peginterferon α-2a Combination Therapies in Chronic Hepatitis C Patients Who Relapsed After or Had a Viral Breakthrough on Therapy with Standard Interferon α-2b Plus Ribavirin: A Pilot Study of Efficacy and Safety , 2005, Digestive Diseases and Sciences.
[86] S. Lemon,et al. Regulating Intracellular Antiviral Defense and Permissiveness to Hepatitis C Virus RNA Replication through a Cellular RNA Helicase, RIG-I , 2005, Journal of Virology.
[87] R. Andrade,et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. , 2005, Gastroenterology.
[88] V. de Lédinghen,et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. , 2005, Gastroenterology.
[89] Y. Ohashi,et al. Antiviral Therapy for Cirrhotic Hepatitis C: Association with Reduced Hepatocellular Carcinoma Development and Improved Survival , 2005, Annals of Internal Medicine.
[90] F. Fabrizi,et al. Meta‐analysis: effect of hepatitis C virus infection on mortality in dialysis , 2004, Alimentary pharmacology & therapeutics.
[91] Y. Imai,et al. Interferon therapy for aged patients with chronic hepatitis C: improved survival in patients exhibiting a biochemical response , 2004, Journal of Gastroenterology.
[92] T. Kawaguchi,et al. Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling 3. , 2004, The American journal of pathology.
[93] Y. Imai,et al. Characteristics of patients with chronic hepatitis C who develop hepatocellular carcinoma after a sustained response to interferon therapy , 2004, Cancer.
[94] P Martus,et al. Sustained virological response in hepatitis C virus type 1b infected patients is predicted by the number of mutations within the NS5A-ISDR: a meta-analysis focused on geographical differences , 2004, Gut.
[95] Shizuo Akira,et al. The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses , 2004, Nature Immunology.
[96] P. Marcellin,et al. Efficacy and Safety of Two-Dose Regimens of Peginterferon Alpha-2a Compared with Interferon Alpha-2a in Chronic Hepatitis C: A Multicenter, Randomized Controlled Trial , 2004, American Journal of Gastroenterology.
[97] M. Sata,et al. A significant reduction in serum alanine aminotransferase levels after 3-month iron reduction therapy for chronic hepatitis C: a multicenter, prospective, randomized, controlled trial in Japan , 2004, Journal of Gastroenterology.
[98] William M. Lee,et al. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. , 2004, Gastroenterology.
[99] L. Seeff,et al. Aasld Practice Guideline Diagnosis, Management, and Treatment of Hepatitis C , 2003 .
[100] P. Marcellin,et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. , 2004, Annals of internal medicine.
[101] K. Koike,et al. Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. , 2004, Gastroenterology.
[102] Aniruddha M. Deshpande,et al. Standardized Reporting of Clinical Practice Guidelines: A Proposal from the Conference on Guideline Standardization , 2003, Annals of Internal Medicine.
[103] M. Manns,et al. Early virologic response to treatment with peginterferon alfa‐2b plus ribavirin in patients with chronic hepatitis C , 2003, Hepatology.
[104] M. Russo,et al. Interferon monotherapy for dialysis patients with chronic hepatitis C: an analysis of the literature on efficacy and safety , 2003, American Journal of Gastroenterology.
[105] Lin Deng,et al. Identification of Hepatitis C Virus (HCV) Subtype 1b Strains That Are Highly, or Only Weakly, Associated with Hepatocellular Carcinoma on the Basis of the Secondary Structure of an Amino-Terminal Portion of the HCV NS3 Protein , 2003, Journal of Clinical Microbiology.
[106] K. Eguchi,et al. Hepatic steatosis is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C virus infection , 2003, Cancer.
[107] G. Marchesini,et al. Nutritional supplementation with branched-chain amino acids in advanced cirrhosis: a double-blind, randomized trial. , 2003, Gastroenterology.
[108] P. Heinrich,et al. IFN‐α antagonistic activity of HCV core protein involves induction of suppressor of cytokine signaling‐3 , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[109] Y. Shiratori,et al. Interferon Therapy after Tumor Ablation Improves Prognosis in Patients with Hepatocellular Carcinoma Associated with Hepatitis C Virus , 2003, Annals of Internal Medicine.
[110] Yoshiyuki Suzuki,et al. Efficacy of interferon monotherapy to 394 consecutive naive cases infected with hepatitis C virus genotype 2a in Japan: therapy efficacy as consequence of tripartite interaction of viral, host and interferon treatment-related factors. , 2002, Journal of hepatology.
[111] William M. Lee,et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. , 2002, Gastroenterology.
[112] R. Cortese,et al. The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus , 2002, The EMBO journal.
[113] Dieter Häussinger,et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. , 2002, The New England journal of medicine.
[114] Warren S. Alexander,et al. Suppressors of cytokine signalling (SOCS) in the immune system , 2002, Nature Reviews Immunology.
[115] S. Kubo,et al. Randomized clinical trial of long‐term outcome after resection of hepatitis C virus‐related hepatocellular carcinoma by postoperative interferon therapy , 2002, The British journal of surgery.
[116] D. Pessayre,et al. Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: a model of viral‐related steatosis , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[117] Frank Scholle,et al. Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein. , 2002, Gastroenterology.
[118] T. Takayama,et al. Normalization of elevated hepatic 8-hydroxy-2'-deoxyguanosine levels in chronic hepatitis C patients by phlebotomy and low iron diet. , 2001, Cancer research.
[119] K. Shimotohno,et al. Effects of Mutation in Hepatitis C Virus Nonstructural Protein 5A on Interferon Resistance Mediated by Inhibition of PKR Kinase Activity in Mammalian Cells , 2001, Microbiology and immunology.
[120] P. Marcellin,et al. Prospective study on anti‐hepatitis C virus–positive patients with persistently normal serum alanine transaminase with or without detectable serum hepatitis C virus RNA , 2001, Hepatology.
[121] Kenneth Koury,et al. For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .
[122] E. Schiff,et al. A randomized, double‐blind trial comparing pegylated interferon alfa‐2b to interferon alfa‐2b as initial treatment for chronic hepatitis C , 2001, Hepatology.
[123] G. Barber,et al. Hepatitis C Virus Nonstructural 5A Protein Induces Interleukin-8, Leading to Partial Inhibition of the Interferon-Induced Antiviral Response , 2001, Journal of Virology.
[124] K. Koike,et al. Oxidative stress in the absence of inflammation in a mouse model for hepatitis C virus-associated hepatocarcinogenesis. , 2001, Cancer research.
[125] A. Tamori,et al. Effects of Long-Term Postoperative Interferon- Therapy on Intrahepatic Recurrence after Resection of Hepatitis C VirusRelated Hepatocellular Carcinoma , 2001, Annals of Internal Medicine.
[126] M. Shiffman,et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. , 2000, The New England journal of medicine.
[127] K. Chayama,et al. Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor—A prospective randomized study of hepatitis C virus–related liver cancer , 2000, Hepatology.
[128] H. Bonkovsky,et al. Iron reduction as an adjuvant to interferon therapy in patients with chronic hepatitis C who have previously not responded to interferon: A multicenter, prospective, randomized, controlled trial , 2000, Hepatology.
[129] E. Tanaka,et al. Natural history of acute hepatitis C , 2000, Journal of gastroenterology and hepatology.
[130] M. Sata,et al. Histologic Improvement of Fibrosis in Patients with Hepatitis C Who Have Sustained Response to Interferon Therapy , 2000, Annals of Internal Medicine.
[131] R. Torella,et al. Natural history of hepatitis C virus carriers with persistently normal aminotransferase levels. , 2000, Gastroenterology.
[132] R. Levine,et al. Iron reduction before and during interferon therapy of chronic hepatitis C: Results of a multicenter, randomized, controlled trial , 2000, Hepatology.
[133] L. Seeff,et al. 45-Year Follow-up of Hepatitis C Virus Infection in Healthy Young Adults , 2000, Annals of Internal Medicine.
[134] J. Herrera. Iron depletion is not effective in inducing a virologic response in patients with chronic hepatitis C who failed to respond to interferon therapy , 1999, American Journal of Gastroenterology.
[135] C. Garret,et al. A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia. , 1999, Gastroenterology.
[136] Y. Rino,et al. Association between high serum alanine aminotransferase levels and more rapid development and higher rate of incidence of hepatocellular carcinoma in patients with hepatitis C virus‐associated cirrhosis , 1999, Cancer.
[137] Yasuyuki Arakawa,et al. Interferon Therapy Reduces the Risk for Hepatocellular Carcinoma: National Surveillance Program of Cirrhotic and Noncirrhotic Patients with Chronic Hepatitis C in Japan , 1999, Annals of Internal Medicine.
[138] D. R. Taylor,et al. Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein. , 1999, Science.
[139] E. Kenny‐Walsh. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. , 1999, The New England journal of medicine.
[140] K. Chayama,et al. Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: A long‐term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis , 1999, Hepatology.
[141] T. Okanoue,et al. Interferon therapy lowers the rate of progression to hepatocellular carcinoma in chronic hepatitis C but not significantly in an advanced stage: a retrospective study in 1148 patients. Viral Hepatitis Therapy Study Group. , 1999, Journal of hepatology.
[142] L. Rostaing,et al. Pharmacokinetics of alphaIFN-2b in chronic hepatitis C virus patients undergoing chronic hemodialysis or with normal renal function: clinical implications. , 1998, Journal of the American Society of Nephrology : JASN.
[143] J. Hoefs,et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. , 1998, The New England journal of medicine.
[144] William M. Lee,et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. , 1998, The New England journal of medicine.
[145] P. Marcellin,et al. Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus , 1998, The Lancet.
[146] M. Houghton,et al. Binding of hepatitis C virus to CD81. , 1998, Science.
[147] Y. Imai,et al. Relation of Interferon Therapy and Hepatocellular Carcinoma in Patients with Chronic Hepatitis C , 1998, Annals of Internal Medicine.
[148] M. Rapicetta,et al. Correlation between virus genotype and chronicity rate in acute hepatitis C. , 1998, Journal of hepatology.
[149] M. Mizokami,et al. A pilot randomized, controlled trial of the effect of iron depletion on long-term response to α-interferon in patients with chronic hepatitis C , 1998 .
[150] Aril Frydén,et al. Randomised, double-blind, placebo-controlled trial of interferon α-2b with and without ribavirin for chronic hepatitis C , 1998, The Lancet.
[151] H. Scholte,et al. Mitochondrial Injury , 1997, Drug safety.
[152] K. Chayama,et al. The long term efficacy of glycyrrhizin in chronic hepatitis C patients , 1997, Cancer.
[153] P. Bedossa,et al. Natural history of liver fibrosis progression in patients with chronic hepatitis C , 1997, The Lancet.
[154] N Enomoto,et al. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. , 1996, The New England journal of medicine.
[155] M. Urdea,et al. Efficacy of interferon alfa therapy in chronic hepatitis C patients depends primarily on hepatitis C virus RNA level , 1995, Hepatology.
[156] S. Seki,et al. Randomised trial of effects of interferon-α on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis , 1995, The Lancet.
[157] N. Enomoto,et al. Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b. Sensitivity to interferon is conferred by amino acid substitutions in the NS5A region. , 1995, The Journal of clinical investigation.
[158] M. Tong,et al. Clinical outcomes after transfusion-associated hepatitis C. , 1995, The New England journal of medicine.
[159] C. Gil,et al. Persistent hepatitis C viremia after acute self‐limiting posttransfusion hepatitis C , 1995, Hepatology.
[160] K. Masuko,et al. Hepatitis C virus antibodies, viral RNA and genotypes in sera from patients on maintenance haemodialysis , 1994, Journal of viral hepatitis.
[161] K. Chayama,et al. Factors predictive of response to interferon‐α therapy in hepatitis C virus infection , 1994, Hepatology.
[162] K. Chayama,et al. A multivariate analysis of risk factors for hepatocellular carcinogenesis: A prospective observation of 795 patients with viral and alcoholic cirrhosis , 1993, Hepatology.
[163] G. Davis,et al. Significance of serum hepatitis C virus RNA levels in chronic hepatitis C , 1993, The Lancet.
[164] F. Iber,et al. Long-Term Mortality after Transfusion-Associated Non-A, Non-B Hepatitis , 1992 .
[165] R. Goldwyn. FOLLOW-UP , 1992, Science.
[166] R. Purcell,et al. Interrelationship of blood transfusion, non‐A, non‐B hepatitis and hepatocellular carcinoma: Analysis by detection of antibody to hepatitis C virus , 1990, Hepatology.
[167] D. Laurent,et al. A randomized study , 2010 .
[168] Y. Shaobin,et al. AASLD PRACTICE GUIDELINES:diagnosis,management,and treatment of hepatitis C:an update , 2009 .
[169] Hirokazu Takahashi,et al. Whole-Body Insulin Sensitivity Index Is a Highly Specific Predictive Marker for Virological Response to Peginterferon Plus Ribavirin Therapy in Chronic Hepatitis C Patients with Genotype 1b and High Viral Load , 2008, Digestive Diseases and Sciences.
[170] N. Hayashi,et al. Virological Response in Patients with Hepatitis C Virus Genotype 1b and a High Viral Load , 2008, Clinical drug investigation.
[171] K. Okita,et al. Hepatitis C virus-induced reactive oxygen species raise hepatic iron level in mice by reducing hepcidin transcription. , 2008, Gastroenterology.
[172] 仁科 惣治. Hepatitis C virus-induced reactive oxygen species raise hepatic iron level in mice by reducing hepcidin transcription , 2008 .
[173] M. Jadoul,et al. KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease , 2008 .
[174] R. D. de Knegt,et al. Gamma-glutamyltransferase and rapid virological response as predictors of successful treatment with experimental or standard peginterferon-alpha-2b in chronic hepatitis C non-responders. , 2007, Liver international : official journal of the International Association for the Study of the Liver.
[175] K. Reddy,et al. Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment. , 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[176] William M. Lee,et al. Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C. , 2007, Gastroenterology.
[177] A. Jaffe,et al. Reduction of infarct size in patients with inferior infarction with intravenous glyceryl trinitrate. A randomised study. , 1983, British heart journal.
[178] G. Sen,et al. Viruses and interferons. , 2001, Annual review of microbiology.
[179] P. Bonis. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. , 1999, The New England journal of medicine.
[180] P. Marcellin,et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT) , 1998, Lancet.
[181] O. Weiland,et al. Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group. , 1998, Lancet.
[182] E. Wildhirt. Experience in Germany with Glycyrrhizinic Acid for the Treatment of Chronic Viral Hepatitis , 1994 .
[183] J. Kirkwood,et al. Interferon therapy. , 1982, World Health Organization technical report series.
[184] N. Grace. Hepatic iron overload. , 1973, Postgraduate medicine.